Travere Therapeutics, Inc. TVTX R2K
Healthcare · Biotechnology · United States
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
READ MORE ›$47.18
+214.11% 1Y
Market & Price
Market Cap
$4.39B
Current Price
$47.18
High / Low (52W)
$47.76 / $14.08
Beta
1.14
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
9.59
PEG Ratio
-
Book Value
$1.07
Price to Book
44.18
P/S
8.18
EV/EBITDA
276.63
Dividend Yield
-
Profitability & Returns
ROCE
-8.65%
ROE
-69.38%
ROA
-6.46%
Profit Margin
-4.00%
Op Margin
-29.02%
EPS (Latest Qtr)
$-0.40
EPS (TTM)
$-0.50
Balance Sheet & Liquidity
Debt/Equity
3.32
Quick Ratio
2.82
Current Ratio
3.13
Debt
$327.66M
Total Assets
$605.19M
Current Assets
$437.56M
Working Capital
$277.66M
Ownership
Promoter Holding
0.80%
Chg in Prom Hold
-
FII / Inst Holding
114.03%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$4.45B
Total Revenue (TTM)
$536.20M
EBITDA
$16.09M
Free Cash Flow
$-51.17M
Operating Cash Flow
$39.61M
Shares Outstanding
92.99M
Gross Margin
55.95%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
64.89%
Profit 5Y
30.28%
Revenue (YoY)
55.60%
Earnings (YoY)
-
PROS
- Compounding revenue at 64.9% over 5 years.
- Profit CAGR of 30.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TVTX Travere Therapeutics, Inc. R2K | 47.18 | - | $4.39B | - | -8.65% | -69.38% | 64.89% | 30.28% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 33.62M | 38.80M | 40.34M | 42.18M | 38.43M | 41.34M | 40.71M | 43.77M | 39.57M | 44.71M | 44.37M | 46.69M | 47.77M | 48.43M | 51.14M | 50.98M | 47.41M | 54.62M | 68.22M | 23.41M | 28.63M | 28.07M | 29.34M | 30.89M | 32.20M | 37.09M | 45.06M | 41.37M | 54.12M | 62.90M | - | 81.73M | 114.45M | 164.86M | 129.69M | 127.20M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.10M | 1.52M | 1.58M | 2.55M | 26.77M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 64.63M | 112.93M | 163.27M | 127.14M | 100.43M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 107.30M | 125.58M | 138.34M | 159.56M | 137.35M |
| Operating Income | -8.24M | -11.38M | -20.37M | -18.22M | -14.41M | -13.60M | -10.61M | -15.18M | -17.91M | -21.56M | -35.58M | -4.99M | -38.23M | -36.53M | -34.44M | -28.17M | -15.07M | -23.11M | -19.43M | -118.55M | -47.55M | -35.31M | -31.71M | -71.98M | -78.53M | -82.60M | -86.70M | -97.37M | -103.95M | -92.58M | -94.23M | -139.24M | -67.70M | -56.15M | - | -42.67M | -12.65M | 24.93M | -32.43M | -36.91M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -25.53M | 4.13M | 44.25M | -632.00K | -9.21M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.86M | 2.85M | 2.75M | 2.30M | 2.30M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -41.19M | -12.73M | 25.71M | -21.07M | -36.72M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.00K | 20.00K | 8.00K | 921.00K | -120.00K |
| Net Income | 11.22M | -13.40M | -37.11M | -8.60M | -11.09M | -13.23M | -17.79M | -17.62M | -18.38M | -22.33M | -54.52M | -7.46M | -40.98M | -38.70M | -36.49M | -30.26M | 808.00K | -26.07M | -22.55M | -121.62M | -53.87M | -39.01M | -35.64M | -75.97M | -67.03M | -69.66M | -65.82M | -86.33M | -85.63M | 150.74M | -90.17M | -136.06M | -70.41M | -54.81M | - | -41.23M | -12.76M | 25.71M | 2.73M | -37.10M |
| Diluted EPS | -0.08 | -0.37 | -1.00 | -0.39 | -0.32 | -0.34 | -0.46 | -0.55 | -0.46 | -0.56 | -1.34 | -0.18 | -0.99 | - | - | - | 0.02 | -0.58 | -0.44 | - | -0.96 | -0.64 | -0.59 | -1.20 | -1.05 | -1.09 | -1.03 | -1.27 | -1.13 | 1.97 | -1.18 | -1.76 | -0.91 | -0.70 | - | -0.47 | -0.14 | 0.28 | 0.03 | -0.40 |
| R&D Expense | 14.67M | 17.68M | 18.41M | - | 20.86M | 19.48M | 19.61M | - | 24.64M | 34.46M | 32.45M | - | 33.44M | 37.93M | 33.22M | - | 30.25M | 30.79M | 32.35M | - | 47.95M | 51.81M | 48.41M | - | - | - | - | 7.50M | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Feb 2011 | Feb 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 133.59M | 154.94M | 164.25M | 175.34M | 198.32M | - | 109.46M | 145.24M | 233.18M | 490.73M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 4.42M | 11.45M | 7.74M | 10.34M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | 105.04M | 133.79M | 225.43M | 480.39M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 424.85M | 510.53M | 546.82M | 543.21M |
| Operating Income | - | - | -30.26M | -24.77M | -79.81M | -50.75M | -58.21M | -53.79M | -80.04M | -137.36M | -176.16M | - | -319.81M | -376.74M | -321.39M | -62.82M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -299.42M | -326.25M | -265.77M | 22.22M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 11.01M | 11.33M | 11.18M | 10.75M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -331.15M | -376.11M | -320.51M | -49.27M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 313.00K | 223.00K | 120.00K | 988.00K |
| Net Income | -23.02K | -14.82K | -30.34M | -34.62M | -110.94M | 117.24M | -47.90M | -59.73M | -102.68M | -146.43M | -169.43M | - | -278.48M | -111.40M | -321.55M | -25.55M |
| Diluted EPS | - | - | - | -2.44 | -4.43 | 3.17 | -1.29 | -1.54 | -2.54 | -3.46 | -3.56 | - | -4.37 | -1.50 | -4.08 | -0.29 |
| R&D Expense | - | - | 662.50K | 7.08M | 47.80M | 50.43M | 70.82M | 78.17M | 123.76M | 140.96M | - | - | 7.50M | - | - | - |
Compounded Sales Growth
| 5 Years: | 64.89% |
| 1 Year: | 55.60% |
Compounded Profit Growth
| 5 Years: | 30.28% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +214.11% |
| 6 Months: | +31.02% |
| 3 Months: | +58.38% |
| 1 Month: | +17.66% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Feb 2011 | Dec 2011 | Feb 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 19.57K | - | 2.39M | 20.50M | 135.47M | 512.26M | 525.28M | 520.35M | 709.16M | 604.80M | 607.44M | - | 672.59M | 788.91M | 594.12M | 605.19M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 486.44M | 616.77M | 416.70M | 437.56M |
| Cash & Equivalents | - | 10.05K | - | 11.00K | 6.00M | 18.20M | 37.80M | 41.00M | 99.39M | 102.87M | 62.44M | 84.77M | - | 61.69M | 58.18M | 58.53M | 93.03M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.52M | 9.41M | 6.20M | 5.88M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.65M | 21.18M | 27.12M | 80.13M |
| Total Liabilities | - | - | - | 5.80M | 40.17M | 172.72M | 212.29M | 217.51M | 227.21M | 390.91M | 383.60M | 396.23M | - | 629.73M | 588.10M | 535.05M | 490.36M |
| Current Liabilities | - | 555.86K | - | 5.80M | 36.56M | 107.54M | 86.98M | 83.26M | 85.67M | 104.62M | 95.45M | 92.66M | - | 142.16M | 177.91M | 200.75M | 159.90M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 375.55M | 377.26M | 310.31M | 311.72M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 407.49M | 404.78M | 401.58M | 328.73M |
| Total Equity | -60.26K | -536.28K | -63.08K | -3.41M | -19.67M | -37.25M | 299.97M | 307.77M | 293.13M | 318.25M | 221.20M | 211.21M | - | 42.85M | 200.81M | 59.08M | 114.83M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 64.29M | 75.37M | 87.45M | 90.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Feb 2011 | Feb 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -689 | -49 | -2.74M | -17.59M | - | -1.39M | -3.44M | 7.40M | -24.96M | -58.21M | -42.74M | - | -186.29M | -280.02M | -237.47M | 37.78M |
| Investing Cash Flow | - | - | -1.70M | -5.41M | - | -80.60M | 10.37M | 45.60M | -203.29M | 19.86M | -61.33M | - | -32.55M | 55.78M | 99.33M | 27.89M |
| Financing Cash Flow | - | - | 4.44M | 28.98M | 95.32M | 101.60M | -3.85M | 5.45M | 231.86M | -2.08M | 127.71M | - | 117.57M | 218.75M | 139.42M | -33.47M |
| Capital Expenditure | - | - | -24.77K | -117.00K | -663.00K | -22.00K | -1.43M | -887.00K | -727.00K | -195.00K | -6.77M | - | -28.37M | -41.59M | -101.21M | -58.16M |
| Free Cash Flow | - | - | -2.76M | -17.71M | - | -1.41M | -4.87M | 6.52M | -25.68M | -58.41M | -49.51M | - | -214.66M | -321.61M | -338.69M | -20.37M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -101.27M | -5.49M | 1.27M | 32.21M |
| Share Buybacks | - | - | - | 958.00K | 2.26M | 0 | 0 | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Feb 2011 | Feb 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | 96.0% | 92.1% | 96.7% | 97.9% |
| Operating Margin % | - | - | - | - | - | - | -43.6% | -34.7% | -48.7% | -78.3% | -88.8% | - | -292.2% | -259.4% | -137.8% | -12.8% |
| Net Margin % | - | - | - | - | - | - | -35.9% | -38.6% | -62.5% | -83.5% | -85.4% | - | -254.4% | -76.7% | -137.9% | -5.2% |
| ROE % | 38.2% | 23.5% | 890.4% | 176.1% | 297.8% | 39.1% | -15.6% | -20.4% | -32.3% | -66.2% | -80.2% | - | -649.9% | -55.5% | -544.3% | -22.2% |
| ROCE % | - | - | 887.9% | 154.2% | -285.7% | -11.9% | -13.2% | -12.4% | -13.2% | -27.0% | -34.2% | - | -60.3% | -61.7% | -81.7% | -14.1% |
Shareholding Pattern
Insiders
0.80%
Institutions
114.03%
Public Float
114.95%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Janus Henderson Group PLC | 12.28% | 11.42M | $538.78M |
| 2 | FMR, LLC | 11.79% | 10.97M | $517.47M |
| 3 | Blackrock Inc. | 8.38% | 7.79M | $367.63M |
| 4 | State Street Corporation | 5.33% | 4.96M | $234.01M |
| 5 | Armistice Capital, LLC | 5.27% | 4.90M | $231.06M |
| 6 | Perceptive Advisors Llc | 4.45% | 4.14M | $195.45M |
| 7 | Vanguard Capital Management LLC | 4.35% | 4.05M | $190.88M |
| 8 | Nomura Asset Management International Inc | 3.52% | 3.27M | $154.30M |
| 9 | Geode Capital Management, LLC | 2.55% | 2.37M | $111.80M |
| 10 | Renaissance Technologies, LLC | 2.11% | 1.97M | $92.79M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TVTX
No recent headlines available.